The Effects of Mindfulness-Based Interventions on Diabetes-Related Distress, Quality of Life, and Metabolic Control Among Persons with Diabetes: A Meta-Analytic Review.
Study Goal
The researchers aimed to evaluate the effectiveness of mindfulness-based interventions (MBIs) in reducing diabetes-related distress (DRD) and improving metabolic control and quality of life in individuals with Type 1 and Type 2 diabetes.
Results Summary
The meta-analysis found small-to-moderate effect sizes for MBIs in improving DRD and metabolic control from pretreatment to posttreatment, but these effects were unreliable at follow-up. Quality of life showed a moderate effect size at posttreatment but not at follow-up, while control group comparisons were unreliable for all outcomes.
Population
Individuals with Type 1 and Type 2 diabetes.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Mindfulness-based interventions (MBIs) | increase | psychological outcomes | people with multiple chronic health conditions, including diabetes | - | improved | #1 |
Mindfulness-based interventions (MBIs) | decrease | diabetes-related distress (DRD) | people with Type 1 and Type 2 diabetes | - | targeted | #2 |
Mindfulness-based interventions (MBIs) | improvement | diabetes-related outcomes | people with Type 1 and Type 2 diabetes | - | targeted | #3 |
Mindfulness-based interventions (MBIs) | decrease | DRD | people with diabetes | - | designed to improve | #4 |
Mindfulness-based interventions (MBIs) | increase | quality of life | people with diabetes | - | designed to improve | #5 |
Mindfulness-based interventions (MBIs) | improvement | measures of metabolic control | people with diabetes | - | designed to improve | #6 |
Mindfulness-based interventions (MBIs) | decrease | DRD | treatment group participants | small-to-moderate effect sizes | uncovered small-to-moderate effect sizes for | #7 |
Mindfulness-based interventions (MBIs) | improvement | metabolic control | treatment group participants | small-to-moderate effect sizes | uncovered small-to-moderate effect sizes for | #8 |
Mindfulness-based interventions (MBIs) | no change | DRD | treatment group participants | small and unreliable | pretreatment to follow-up comparisons were small and unreliable for | #9 |
Mindfulness-based interventions (MBIs) | no change | metabolic control | treatment group participants | small and unreliable | pretreatment to follow-up comparisons were small and unreliable for | #10 |
Mindfulness-based interventions (MBIs) | no change | all outcomes | control groups | unreliable | all comparisons were unreliable for | #11 |
Mindfulness-based interventions (MBIs) | increase | quality of life outcomes | treatment group participants | moderate effect size | found a moderate effect size for | #12 |
Mindfulness-based interventions (MBIs) | no change | quality of life outcomes | treatment group participants | - | not at follow-up comparisons for | #13 |
Mindfulness-based interventions (MBIs) | no change | treatment-control comparisons | treatment and control groups | unreliable | all other effect sizes were unreliable for | #14 |
Mindfulness-based interventions (MBIs) have improved psychological outcomes for multiple chronic health conditions, including diabetes. A meta-analytic review of the literature was conducted on all located studies (n = 14) investigating MBIs that targeted diabetes-related distress (DRD) and diabetes-related outcomes among people with Type 1 and Type 2 diabetes. PsychInfo, PubMed, Medline, and Web of Science were searched for MBIs that were designed to improve DRD and other secondary outcomes, including quality of life and measures of metabolic control. A meta-analysis of these outcomes uncovered small-to-moderate effect sizes for intervention studies measuring pretreatment to posttreatment changes in DRD and metabolic control among treatment group participants. However, the pretreatment to follow-up comparisons for DRD and metabolic control were small and unreliable. For control groups, all pre-treatment to post-treatment and pre-treatment to follow-up comparisons were unreliable for all outcomes. A moderate effect size for treatment-control comparisons was found for intervention studies measuring quality of life outcomes at posttreatment, but not at follow-up comparisons. All other effect sizes for treatment-control comparisons were unreliable. Limitations and implications for MBIs among individuals with diabetes are discussed.